Astellas Pharma vs. Apsen: Appeal Dismissed in Mirabegron Patent Case in São Paulo
Was möchten Sie als Nächstes tun?
Wählen Sie Ihren Weg entsprechend Ihren aktuellen Bedürfnissen:
📋 Fallzusammenfassung
| Fallbezeichnung | Astellas Pharma, Inc. v. Apsen Farmacêutica S.A. |
| Fallnummer | 2131917-74.2024.8.26.0000 |
| Gericht | Court of Justice of São Paulo, Brazil |
| Berufung zurückgewiesen | August 21, 2024 |
| Ergebnis | Plaintiff Win — Appeal Dismissed |
| Streitige Patente | |
| Beschuldigte Produkte | Apsen’s Mirabegron Generic Product (allegedly infringing MYRBETRIC®) |
Fallübersicht
Die Parteien
⚖️ Kläger
Tokyo-headquartered global pharmaceutical company with a substantial IP portfolio spanning urology, oncology, and transplantation therapeutics. Holder of patent BRPI0213570B1.
🛡️ Beklagter
Well-established Brazilian pharmaceutical company with a strong presence in the domestic generics and branded generics market.
Das streitige Patent
This case centered on **BRPI0213570B1**, a Brazilian patent corresponding to Astellas’s proprietary mirabegron compound technology. Mirabegron operates as a beta-3 adrenergic receptor agonist—a mechanism of action distinct from traditional anticholinergic OAB treatments—and represents a significant therapeutic advance. The patent protects core formulation and/or compound aspects of this technology in Brazil.
- • BRPI0213570B1 — Mirabegron compound technology for overactive bladder
Developing a Mirabegron-based Product?
Check if your pharmaceutical formulation might infringe this or related patents before launch.
Das Urteil und die rechtliche Analyse
Ergebnis
The Court of Justice of São Paulo ruled unequivocally: “The claim of the present appeal is denied.” The appeal was dismissed in its entirety, reinforcing Astellas’s IP position in Brazil. No specific damages amount was disclosed, consistent with the appellate procedural posture where the court was reviewing, rather than reassessing, underlying infringement determinations.
Wichtige rechtliche Fragen
The Court of Justice of São Paulo’s dismissal of the appeal indicates that Apsen failed to persuade the appellate panel that reversible legal or factual errors occurred in the underlying proceedings. Brazilian appellate courts apply a structured review standard—appellants must demonstrate specific grounds for reversal. The clean dismissal here suggests the appellate arguments did not meet this threshold.
While the specific legal reasoning of the panel was not detailed in the provided case data, the outcome is consistent with Brazilian courts’ increasing rigor in evaluating pharmaceutical patent challenges. Brazil’s IP legal framework under Lei No. 9.279/96 (Industrial Property Law) provides robust protection for validly granted patents, and the INPI’s examination process has yielded patents that Brazilian courts have demonstrated willingness to enforce.
Freedom-to-Operate-Analyse (FTO)
This case highlights critical IP risks in mirabegron development. Choose your next step:
📋 Die Auswirkungen dieses Falls verstehen
Informieren Sie sich über die spezifischen Risiken und Auswirkungen dieses Arzneimittelprozesses.
- View all related patents for mirabegron technology
- See which companies are most active in beta-3 agonist IP
- Understand claim construction patterns relevant to pharma
🔍 Das Risiko meines Produkts überprüfen
Run a comprehensive FTO analysis for your mirabegron formulation or related technology.
- Geben Sie Ihre Rezepturdetails oder technischen Merkmale ein.
- AI identifies potentially blocking patents (e.g., BRPI0213570B1)
- Get actionable risk assessment report for Brazil
Hochrisikogebiet
Mirabegron Formulations & Derivatives
1 Streitgegenständliches Patent
BRPI0213570B1
Design-Around-Optionen
Available, but challenging for core compounds
✅ Wichtigste Erkenntnisse
Brazilian appellate courts show rigor in pharmaceutical IP disputes, often upholding lower court infringement rulings.
Verwandte Rechtsprechung suchen →Appeal strategies in Brazilian IP cases must introduce distinct legal arguments—rearticulation of first-instance positions carries high dismissal risk.
Präzedenzfälle erkunden →Consider parallel INPI nullity proceedings as an important tactical option for patent challengers operating alongside court litigation.
Learn about INPI proceedings →Häufig gestellte Fragen
The case involved Brazilian patent BRPI0213570B1, covering mirabegron-related technology, which protects Astellas’s MYRBETRIC® overactive bladder treatment in Brazil.
The Court of Justice of São Paulo denied the appeal in its entirety (Case No. 2131917-74.2024.8.26.0000), concluding on August 21, 2024. The appeal was dismissed without reversal of the underlying infringement action outcome.
The ruling reinforces Brazilian appellate courts’ willingness to uphold pharmaceutical patent enforcement, strengthening originator companies’ litigation posture and raising the strategic bar for generic challengers pursuing appellate remedies.
Sind Sie bereit, Ihre Patentstrategie zu stärken?
Schließen Sie sich den über 18.000 Fachleuten aus dem Bereich des geistigen Eigentums an, die PatSnap Eureka nutzen, um mit KI-gestützter Präzision Recherchen zum Stand der Technik durchzuführen, Patentanmeldungen zu erstellen und Wettbewerbslandschaften zu analysieren.
Referenzen
- Court of Justice of São Paulo (Tribunal de Justiça do Estado de São Paulo) — Case 2131917-74.2024.8.26.0000
- Brazilian National Institute of Industrial Property (INPI) — Patent Database
- Brazilian Industrial Property Law (Lei No. 9.279/96)
- World Intellectual Property Organization (WIPO) — Patent Resources
- PatSnap – Lösungen für den Umgang mit geistigem Eigentum für Anwaltskanzleien
Dieser Artikel dient ausschließlich zu Informationszwecken und stellt keine Rechtsberatung dar. Alle Angaben zu den Fällen stammen aus öffentlich zugänglichen Gerichtsakten. Informationen zu den Funktionen der Plattform finden Sie auf PatSnap.